WO2011088797A1 - Intermediates of neutral endopeptidase inhibitors and preparation method thereof - Google Patents
Intermediates of neutral endopeptidase inhibitors and preparation method thereof Download PDFInfo
- Publication number
- WO2011088797A1 WO2011088797A1 PCT/CN2011/070458 CN2011070458W WO2011088797A1 WO 2011088797 A1 WO2011088797 A1 WO 2011088797A1 CN 2011070458 W CN2011070458 W CN 2011070458W WO 2011088797 A1 WO2011088797 A1 WO 2011088797A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- mmol
- biphenyl
- ylmethyl
- Prior art date
Links
- 0 *N(C(Cc(cc1)ccc1-c1ccccc1)CC1)C1=O Chemical compound *N(C(Cc(cc1)ccc1-c1ccccc1)CC1)C1=O 0.000 description 5
- RCQHQKNHFVXQJN-IBGZPJMESA-N CC(C)(C)OC(N([C@H](Cc(cc1)ccc1-c1ccccc1)CC1)C1=O)=O Chemical compound CC(C)(C)OC(N([C@H](Cc(cc1)ccc1-c1ccccc1)CC1)C1=O)=O RCQHQKNHFVXQJN-IBGZPJMESA-N 0.000 description 2
- MNOOQBYMIWLUIH-OZAIVSQSSA-N CC(C)(C)C(CC(C[C@@H](Cc(cc1)ccc1-c1ccccc1)N1C(OC(C)(C)C)=O)C1=O)=O Chemical compound CC(C)(C)C(CC(C[C@@H](Cc(cc1)ccc1-c1ccccc1)N1C(OC(C)(C)C)=O)C1=O)=O MNOOQBYMIWLUIH-OZAIVSQSSA-N 0.000 description 1
- PSLXDXAKXLAOHT-FQEVSTJZSA-N CC(C)(C)OC(N([C@H](Cc(cc1)ccc1-c1ccccc1)CC1=C)C1=O)=O Chemical compound CC(C)(C)OC(N([C@H](Cc(cc1)ccc1-c1ccccc1)CC1=C)C1=O)=O PSLXDXAKXLAOHT-FQEVSTJZSA-N 0.000 description 1
- ZWSUFNTXIHALLB-QHCPKHFHSA-N COc1ccc(CN([C@H](Cc(cc2)ccc2-c2ccccc2)CC2)C2=O)cc1 Chemical compound COc1ccc(CN([C@H](Cc(cc2)ccc2-c2ccccc2)CC2)C2=O)cc1 ZWSUFNTXIHALLB-QHCPKHFHSA-N 0.000 description 1
- SOBIWLIICMUXJK-INIZCTEOSA-N O=C1N[C@H](Cc(cc2)ccc2-c2ccccc2)CC1 Chemical compound O=C1N[C@H](Cc(cc2)ccc2-c2ccccc2)CC1 SOBIWLIICMUXJK-INIZCTEOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Definitions
- the invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a y-amino-8-biphenyl-a-methylalkanoic acid, or acid ester, backbone.
- Atrial natriuretic peptides also called atrial natriuretic factors (ANF) have diuretic, natriuretic and vasorelaxant functions in mammals.
- ANF peptides are metabolically inactivated, in particular by a degrading enzyme which has been recognized to correspond to the enzyme neutral endopeptidase (NEP, EC 3.4.24.1 1 ), also responsible for e.g. the metabolic inactivation of enkephalins.
- NEP inhibitors are known which are useful as neutral endopeptidase (NEP) inhibitors, e.g. as inhibitors of the ANF-degrading enzyme in mammals, so as to prolong and potentiate the diuretic, natriuretic and vasodilator properties of ANF in mammals by inhibiting the degradation thereof to less active metabolites.
- NEP inhibitors are thus particularly useful for the treatment of conditions and disorders responsive to the inhibition of neutral endopeptidase (EC 3.4.24.1 1 ), particularly cardiovascular disorders such as hypertension, renal insufficiency including edema and salt retention, pulmonary edema and congestive heart failure.
- NEP-inhibitors Processes for preparing NEP-inhibitors are known.
- US 5 217 996 describes biaryl substituted 4-amino-butyric acid amide derivatives which are useful as neutral endopeptidase (NEP) inhibitors, e.g. as inhibitors of the ANF-degrading enzyme in mammals.
- NEP neutral endopeptidase
- US 5 217 996 discloses the preparation of N-(3-carboxyl-1 -oxopropyl)-(4S)- (p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester.
- WO2009/090251 relates to a reaction route for preparing compound N-t-butoxycarbonyl(4S)-(p-phenylphenylmethyl)-4-amino-2-methylbutanoic acid ethyl ester, or salt thereof, wherein an alternative hydrogenation step provides improved diastereoselectivity compared to that obtained in US 5 217 996.
- a key intermediate of the route described in WO2009/090251 is a compound of formula (1 ),
- Section B in WO2009/090251 discloses different methods for preparing a compound of formula (1 ). All such methods use as starting material a compound of formula (2), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group and R6 and R7 are, independently, an alkyl group, an aryl group, an arylalkyi group, a cycloalkyi group or together R6 and R7 form a cycle, together with the nitrogen to which they are attached, which cycle may be saturated or unsaturated and may optionally contain one or more heteroatoms, such as a nitrogen, oxygen or sulphur, whereby the cycle contains 3 to 8, such as 4 to 7 ring atoms.
- the preparation of a compound of formula (2), or salt thereof comprises reacting a compound of formula (3), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group, with an amine of formula (13), (14) or (15), or mixtures thereof,
- each R6 and each R7 are, independently, an alkyl group, an aryl group, an arylalkyi group, a cycloalkyl group or together R6 and R7 form a cycle, together with the nitrogen to which they are attached, which cycle may be saturated or unsaturated and may optionally contain one or more heteroatoms, such as a nitrogen, oxygen or sulphur, whereby the cycle contains 3 to 8, such as 4 to 7 ring atoms, and each R8 is,
- the object of the present invention is to provide a new process for preparing the compound of formula (1 ), which can be suitable for its commercial scale manufacture.
- the new process, according to the present invention, for producing a compound according to formula (1 ), or salt thereof, as defined herein, is summarized in Scheme 1.
- a compound of formula (3) as described herein, is converted into a compound of formula (1 ), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, according to a method described in Section A.
- WO2008/083967 describes a process for converting a compound of formula (1 ), as described herein, into a NEP inhibitor or prodrug thereof. Therefore, a compound of formula (1 ) can be used as an intermediates in the preparation of NEP inhibitors, or prodrugs thereof, in particular NEP inhibitors comprising a y-amino-8-biphenyl-a- methylalkanoic acid, or acid ester, backbone, preferably N-(3-carboxyl-1 -oxopropyl)- (4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid alkyl ester, such as N- (3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester.
- the invention as a whole comprises the following sections:
- Section A Preparation methods for the compound of formula (1 )
- Section B Novel and inventive compounds
- Section C Examples It is noted that in the present application usually explanations made in one section are also applicable for other sections, unless otherwise stated. For example, the
- the present invention also relates to a process for preparing N- (3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester, or a salt thereof, comprising the manufacture of compound of formula (4), or salt thereof, as defined above.
- Section A Preparation of a compound of formula (1 )
- Section A.1 Synthesis of a compound of formula (4)
- This section relates to a process for the manufacture of a compound of formula (1 ), as defined herein, wherein the conversion of a compound of formula (3), as defined herein, into said compound of formula (1 ) takes place step-wise, i.e. in two separate steps with isolation of the intermediate species of formula (4), as defined herein.
- the present invention relates to a process for preparing a compound of formula (4), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group
- R4 is selected from hydroxyl, alkyl, aryl and arylalkyl
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (3); first with a base and then with a compound of the formula C0 2 or R4COY, wherein Y is halogen or -OR' and wherein R4 and R' are independently selected from alkyl, aryl and arylalkyl, to obtain the compound of formula (4), or salt thereof.
- the present invention relates to a process for preparing a compound of formula (4), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group
- R4 is hydroxyl
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (3); first with a base and then with a compound of the formula C0 2 to obtain the compound of formula (4), or salt thereof.
- Suitable bases for the conversion of a compound of formula (3), preferably of formula (3a), as described herein, into a compound of formula (4), preferably of formula (4a), as descrbed herein, include:
- alkali metal hydrides eg sodium or potassium hydride
- alkali metal alkoxides eg sodium methoxide, potassium tert-butoxide
- DMPU 1 ,3-dimethyl-3,4,5,6-tetrahydro-2(1 H)-pyrimidinone
- MRa a base of the formula MRa, wherein M is an alkali metal (eg lithium, sodium, potassium) and Ra is alkyl or aryl, for example MRa is methyl lithium, n-butyllithium, sec-butyllithium, tert-butyllithium or phenyllithium;
- M an alkali metal (eg lithium, sodium, potassium)
- Ra alkyl or aryl
- MRa is methyl lithium, n-butyllithium, sec-butyllithium, tert-butyllithium or phenyllithium;
- RcRdNM is lithium bis(trimethylsilyl)amide (LHMDS), sodium bis(trimethylsilyl)amide (NaHMDS), potassium bis(trimethylsilyl)amide (KHMDS), lithium diisopropylamide (LDA) or potassium diisopropylamide; or
- the base is an amine, such as triethylamine, diisopropylethyl amine, optionally in the presence of an additive selected from an alkaline earth metal halide, such as magnesium chloride, magnesium bromide and magnesium iodide.
- an alkaline earth metal halide such as magnesium chloride, magnesium bromide and magnesium iodide.
- the base is LHMDS, lithium diisopropylamide or sodium hydride, most preferably LHMDS.
- Section A.2 Synthesis of a compound of formula (1 ) from a compound of formula (4)
- the present invention relates to a process for preparing a compound of formula (1 ), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (1 );
- R1 is hydrogen or a nitrogen protecting group
- R4 is selected from hydroxyl, alkyl, aryl and arylalkyl
- R1 and R4 are as defined for the compound of formula (4);
- Suitable bases for the conversion of a compound of formula (4), preferably of formula (4a), as described herein, into a compound of formula (1 ), preferably of formula (1 a), as descrbed herein include metal hydrides, such as alkali metal hydrides (eg sodium or potassium hydride), alkali metal alkoxides (eg sodium methoxide, potassium tert- butoxide), an amine, such as diisopropylethylamine, triethylamine, morpholine or 1 ,8- diazabicyclo[5.4.0]undec-7-ene, an inorganic base, such an alkali metal carbonate, such as potassium carbonate, a base of the formula MRa, wherein M is an alkali metal (eg lithium sodium, potassium) and Ra is alkyl or aryl, for example MRa is
- metal hydrides such as alkali metal hydrides (eg sodium or potassium hydride), alkali metal alkoxides (
- alkyl, cycloalkyl, heterocyclyl or silyl and M is an alkali metal (eg lithium sodium,
- RcRdNM is lithium bis(trimethylsilyl)amide (LHMDS),
- KHMDS lithium diisopropylamide
- LDA potassium diisopropylamide
- the conversion of a compound of formula (4), preferably wherein the compound of formula (4) is of the formula (4a), into a compound of formula (1 ), as described above takes place in the presence of a base and an alkali metal salt, such as LiCI. More preferably, this conversion takes place in the presence of a base, an alkali metal salt, such as LiCI, and a drying agent, such as molecular sieves, an alkali metal sulphate (eg sodium sulphate) or an alkaline earth metal sulphate (eg magnesium sulphate).
- Section A.2 Synthesis of a compound of formula (1 ) from a compound of formula (3)
- the present invention relates to a process for preparing a compound of formula (1 ), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (1 );
- R1 is hydrogen or a nitrogen protecting group
- R4 is selected from hydroxyl, alkyl, aryl and arylalkyl
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (3); first with a base and then with a compound of the formula C0 2 or R4COY, wherein Y is halogen or -OR' and wherein R4 and R' are independently selected from alkyl, aryl and arylalkyl, to obtain the compound of formula (4), or salt thereof; and
- R1 is hydrogen or a nitrogen protecting group
- R4 is selected from hydroxyl, alkyl, aryl and arylalkyl; preferably wherein the compound of formula (4) is of the formula (4a)
- the present invention relates to the above process, to convert the compound of formula (3) into the compound of formula (1 ), wherein steps i) and ii) take place via one-pot process, thus without isolation and/or purification of the compound of formula (4).
- the present invention relates to a process for preparing a compound of formula (1 ), or salt thereof,
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (1 );
- R1 is hydrogen or a nitrogen protecting group
- R4 is hydroxyl
- R1 is hydrogen or a nitrogen protecting group
- R1 is as defined for the compound of formula (3); first with a base and then with a compound of the formula C0 2 to obtain the compound of formula (4), or salt thereof;
- R1 is hydrogen or a nitrogen protecting group
- R4 is hydroxyl
- R1 and R4 are as defined for the compound of formula (4);
- the present invention relates to the above process, to convert the compound of formula (3) into the compound of formula (1 ), wherein steps i) and ii) take place via one-pot process, thus without isolation and/or purification of the compound of formula (4).
- Suitable bases for step (i), in the above embodiments, are as those described in Section A.1 .
- step (ii), in the above embodiements are as those described in Section A. 2.
- step (ii), in the above embodiments takes place in the presence of a base and an alkali metal salt, such as LiCI. More preferably, this conversion takes place in the presence of a base, an alkali metal salt, such as LiCI, and a drying agent, such as molecular sieves, an alkali metal sulphate (eg sodium sulphate) or an alkaline earth metal sulphate (eg magnesium sulphate).
- Section B
- R1 is hydrogen or a nitrogen protecting group
- R4 is selected from hydroxyl, alkyl, aryl and arylalkyl
- nitrogen protecting group comprises any group which is capable of reversibly protecting a nitrogen functionality, preferably an amine and/or amide functionality.
- the nitrogen protecting group is an amine protecting group and/or an amide protecting group. Suitable nitrogen protecting groups are
- Preferred nitrogen protecting groups generally comprise:
- Unsubstituted or substituted CrC 6 -alkyl preferably Ci-C 4 -alkyl, more preferably Ci-C 2 - alkyl, most preferably Ci-alkyl, unsubstituted or substituted C 2-4 alkenyl, wherein C-
- aryl preferably phenyl, or an heterocyclic group, preferably pyrrolidinyl, wherein the aryl ring or the heterocyclic group is unsubstituted or substituted by one or more, e.g. two or three, residues, e.g. selected from the group consisting of CrC 7 -alkyl, hydroxy, Ci-C 7 -alkoxy, C 2 -C 8 -alkanoyl-oxy, halogen, nitro, cyano, and CF 3 ; aryl-C1-C2-alkoxycarbonyl (preferably phenyl-C1-C2-alkoxycarbonyl eg.
- nitrogen protecting groups are acetyl, benzyl, cumyl, benzhydryl, trityl, benzyloxycarbonyl (Cbz), 9-fluorenylmethyloxycarbony (Fmoc), benzyloxymethyl (BOM), pivaloyl-oxy-methyl (POM), trichloroethxoycarbonyl (Troc), 1 - adamantyloxycarbonyl (Adoc), allyl, allyloxycarbonyl, trimethylsilyl, tert.-butyl- dimethylsilyl, triethylsilyl (TES), triisopropylsilyl, trimethylsilyethoxymethyl (SEM), t- butoxycarbonyl (BOC), t-butyl, 1-methyl-1 , 1-dimethylbenzyl, (phenyl)methylbenzene, pyrridinyl and pivaloyl.
- nitrogen protecting groups are acetyl, benzyl, benzyloxycarbonyl (Cbz), triethylsilyl (TES), trimethylsilyethoxymethyl (SEM), t- butoxycarbonyl (BOC), pyrrolidinylmethyl and pivaloyl.
- nitrogen protecting groups examples include t-butoxycarbonyl (BOC), benzoyl, styryl, 1 -butenyl, benzyl, p-methoxybenzyl (PMB) and pyrrolidinylmethyl.
- Silyl refers to a group according to the formula -SiR1 1 R12R13, wherein R1 1 , R12 and R13 are, independently of each other, alkyl or aryl.
- Preferred examples for R1 1 , R12 and R13 are methyl, ethyl, isopropyl, t-butyl, phenyl or phenyl-C- M alkyl.
- Alkyl is defined as a radical or part of a radical is a straight or branch (one or, if desired and possible, more times) carbon chain, and is especially CrC 7 -alkyl, preferably Ci-C 4 - alkyl.
- -C 7 - defines a moiety with up to and including maximally 7, especially up to and including maximally 4, carbon atoms, said moiety being branched (one or more times) or straight-chained and bound via a terminal or a non-terminal carbon
- Cycloalkyl is, for example, C 3 -C 7 -cycloalkyl and is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Cyclopentyl and cyclohexyl are preferred.
- Alkoxy is, for example, CrC 7 -alkoxy and is, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy and also includes corresponding pentyloxy, hexyloxy and heptyloxy radicals. CrC 4 alkoxy is preferred.
- C 2 -C 5 -Alkanoyl is preferred, especially acetyl.
- Halo or halogen is preferably fluoro, chloro, bromo or iodo, most preferably, chloro, bromo, or iodo.
- Halo-alkyl is, for example, halo-C-
- -C 7 alkyl is trifluoromethyl.
- Alkenyl may be linear or branched alkyl containing a double bond and comprising preferably 2 to 12 C atoms, 2 to 10 C atoms being especially preferred. Particularly preferred is a linear C 2-4 alkenyl.
- alkyl groups are ethyl and the isomers of propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octacyl and eicosyl, each of which containing a double bond.
- allyl is preferably allyl.
- Alkylene is a bivalent radical derived from Ci -7 alkyl and is especially C 2 -C 7 -alkylene or C 2 - C 7 -alkylene and, optionally, can be interrupted by one or more, e.g. up to three, O, NR14 or S, wherein R14 is alkyl, each of which can be unsubstituted or substituted, by one or more substituents independently selected from for example, CrC 7 -alkyl, Ci-C 7 -alkoxy-Ci- C 7 -alkyl or d-C 7 -alkoxy.
- Alkenylene is a bivalent radical derived from C 2-7 alkenyl and can be interrupted by, one or more, e.g. up to three, O, NR14 or S, wherein R14 is alkyl, and is unsubstituted or substituted by one or more, e.g. up to three, substitutents preferably independently selected from the substitutents mentioned above for alkylene.
- Aryl being a radical or part of a radical is, for example C 6 -ioaryl, and is, preferably a mono- or polycyclic, especially monocyclic, bicyclic or tricyclic aryl moiety with 6 to 10 carbon atoms, preferably phenyl, and which can be unsubstituted or substituted, by one or more substituents independently selected from for example, Ci-C 7 -alkyl, Ci-C 7 -alkoxy-Ci-C 7 - alkyl or Ci-C 7 -alkoxy.
- arylalkyl refers to aryl-Ci-C 7 -alkyl, wherein aryl is as defined herein and is for example benzyl.
- carboxyl refers to -C0 2 H.
- Aryloxy refers to a Aryl-O- wherein aryl is as defined above.
- substitutents preferably independently selected from the Preferred substituents are selected from the group consisting of halo, Ci-C 7 -alkyl, halo-Ci-C 7 -alkyl, Ci-C 7 -alkoxy, halo-CrC 7 -alkoxy, such as trifluoromethoxy and Ci-C 7 -alkoxy-CrC 7 -alkoxy.
- the heterocyclyl is an aromatic ring system, it is also referred to as heteroaryl.
- Sulfonyl is (unsubstituted or substituted) Ci-C 7 -alkylsulfonyl, such as methylsulfonyl, (unsubstituted or substituted) phenyl- or naphthyl-Ci-C 7 -alkylsulfonyl, such as phenyl- methanesulfonyl, or (unsubstituted or substituted) phenyl-or naphthyl-sulfonyl; wherein if more than one substituent is present, e.g.
- the substituents are selected independently from cyano, halo, halo-C-i-C 7 alkyl, halo-C 1 -C 7 -alkyloxy- and C-
- C 1 -C 7 -alkylsulfonyl such as methylsulfonyl
- (phenyl- or naphthyl)-C 1 -C 7 -alkylsulfonyl such as phenylmethanesulfonyl.
- Sulfenyl is (unsubstituted or substituted) C 6 -ioaryl-CrC 7 -alkylsulfenyl or (unsubstituted or substituted) C 6- ioarylsulfenyl, wherein if more than one substituent is present, e.g. one to four substitutents, the substituents are selected independently from nitro, halo, halo-Cr C 7 alkyl and CrC 7 -alkyloxy.
- chiral refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
- tautomer refers in particular to the enol tautomer of the pyrrolidin-2-one moiety of the compounds of the present invention. Additionally, the term “tautomer” also refers in particular to the aldehyde tautomer of compounds of the present invention, e.g. compounds of the formula (6), where such compounds can exists in either an enol or aldehyde form, or mixtures thereof.
- w r on a C-sp 3 represents a covalent bond, wherein the stereochemistry of the bond is not defined.
- wv on a C-sp 3 comprises an (S) configuration as well as an (R)
- the compounds of the present invention can possess one or more asymmetric centers.
- the preferred absolute configurations are as indicated herein specifically.
- Salts are especially pharmaceutically acceptable salts or generally salts of any of the intermediates mentioned herein, where salts are not excluded for chemical reasons the skilled person will readily understand. They can be formed where salt forming groups, such as basic or acidic groups, are present that can exist in dissociated form at least partially, e.g. in a pH range from 4 to 10 in aqueous solutions, or can be isolated especially in solid, especially crystalline, form.
- salt forming groups such as basic or acidic groups
- Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds or any of the intermediates mentioned herein with a basic nitrogen atom (e.g. imino or amino), especially the pharmaceutically acceptable salts.
- Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
- Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, lactic acid, fumaric acid, succinic acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, benzoic acid, methane- or ethane- sulfonic acid, ethane-1 ,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5-naphthalene-disulfonic acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N- propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
- carboxylic, phosphonic, sulfonic or sulfamic acids for example acetic acid,
- salts may also be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl- piperidine or N,N'-dimethylpiperazine.
- bases e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl- piperidine or N,N'-dimethylpiperazine.
- any of the intermediates mentioned herein may also form internal salts.
- any reference to "compounds", “starting materials” and “intermediates” hereinbefore and hereinafter is to be understood as referring also to one or more salts thereof or a mixture of a corresponding free compound, intermediate or starting material and one or more salts thereof, each of which is intended to include also any solvate or salt of any one or more of these, as appropriate and expedient and if not explicitly mentioned otherwise.
- Different crystal forms may be obtainable and then are also included.
- any of the lactams according to the present invention, or salt thereof, wherein R1 is a nitrogen protecting group can be converted into the corresponding lactam, or salt thereof, wherein R1 is a hydrogen, according to standard methods of organic chemistry known in the art, in particular reference is made to conventional nitrogen protecting group methods described in the books mentioned above, in particular, in the relevant sections.
- one-pot means that in a series of reactions, each reaction product is provided for the next reaction without isolation and/or purification.
- purification as used herein wherein, in particular, relates to crystallization, column chromatography or distillation.
- the one-pot processes defined herein encompass not only a series of reactions conducted in a single reaction vessel, but also a series of reactions conducted in a plurality of reaction vessels (e.g., by transferring the reaction mixture from one vessel to other) without isolation and/or purification.
- the one-pot process is conducted in a single reaction vessel.
- phase transfer catalyst refers to a catalytic amount of a chemical agent that enhances the rate of a reaction between chemical species located in different phases (eg. immiscible liquids or solid and liquid) by extracting one of the reactants, most commonly an anion, across the interface into the other phase.
- phase transfer catalysts to be used according to the present invention are quaternary ammonium salts, for example of the formula R m R n R
- prodrug represents in particular compounds which are transformed in vivo to the parent compound, for example, by hydrolysis in blood, for example as described in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; H Bundgaard, ed, Design of Prodrugs, Elsevier, 1985; and Judkins, et al. Synthetic
- Prodrugs therefore include drugs having a functional group which has been transformed into a reversible derivative thereof. Typically, such prodrugs are transformed to the active drug by hydrolysis. As examples may be mentioned the following:
- Carboxylic acid Esters including e.g. alkyl esters
- Alcohol Esters including e.g. sulfates and phosphates as
- Amine Amides carbamates, imines, enamines,
- Prodrugs also include compounds convertible to the active drug by an oxidative or reductive reaction. As examples may be mentioned:
- NEP-inhibitor or a prodrug thereof such as a NEP inhibitor or prodrug thereof comprising a y-amino-8-biphenyl-a-methylalkanoic acid, or acid ester, such as alkyl ester, backbone.
- the NEP-inhibitor is N-(3- carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid or a salt thereof or a prodrug thereof.
- WO2008/083967 describes a process for converting a compound of formula (1 ), as described herein, into a NEP inhibitor or prodrug thereof. Section C: Examples
- reaction mixture is cooled to room temperature, filtered, and the cake is washed with ethyl acetate, the filtrate is washed with 10 % sodium bicarbonate aqueous solution and brine, dried over anhydrous Na 2 S0 4 and concentrate under vacuum, the residue is
- n-butyllithium (56 mL, 2.5 M in hexane, 0.14 mol) is added to the mixture of HMDS (24.2 g, 0.15 mol) in 300 mL dry tetrahydrofuran at -10 °C, the resulting mixture is then stirred for 30 min at -10 °C.
- Benzoyl chloride (15.5 g, 0.1 1 mol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 100 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer, the organic phase is then concentrated in vacuo. Ethyl acetate (200 mL) is added, filtered and the filtrate
- n-butyllithium (2.4 ml_, 2.5 M in hexane, 6 mmol) is added to the mixture of Diisopropylamine (0.71 g, 7 mmol) in 20 ml. dry tetrahydrofuran at -10 °C, the resulting mixture is then stirred for 30 min at -10 °C.
- a mixture of (S)-2-Biphenyl-4-ylmethyl-5-oxo- pyrrolidine-1 -carboxylic acid tert-butyl ester (3a, R1 t-butoxycarbonyl) (1.76 g, 5 mmol) in 5 ml.
- Benzoyl chloride (9.28 g, 66 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 50 ml. saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer, the organic phase is then concentrated in vacuo, ethyl acetate 100 ml.
- reaction mixture is diluted with 5 mL saturated aqueous ammonium chloride solution and 10 mL ethyl acetate, stirred for 15 min, stop stirring, and remove the lower aqueous layer, the organic phase is concentrated to dryness , the residue was purified by column
- reaction mixture is diluted with 5 mL saturated aqueous ammonium chloride solution and 10 mL ethyl acetate, stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- the organic phase is concentrated to dryness , the residue was purified by column
- Acetyl chloride (0.47 g, 6 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 10 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer, the organic phase is then concentrated in vacuo.
- 2,2-dimethyl- propionyl chloride (0.72 g, 6 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 10 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer. the organic phase is then concentrated in vacuo.
- n-butyllithium (56 ml_, 2.5 M in hexane, 0.14 mol) is added to the mixture of HMDS (24.2 g, 0.15 mol) in 300 ml. dry tetrahydrofuran at -10 °C, the resulting mixture is then stirred for 30 min at -10 °C.
- a mixture of (S)-2-biphenyl-4-ylmethyl-5-oxo-pyrrolidine- 1 -carboxylic acid tert-butyl ester (3a, R1 t-butoxycarbonyl) (35.1 g, 0.1 mol) in 50 ml.
- Formaldehyde (37% in water, 24.3 g, 0.3 mol), K 2 C0 3 aqueous solution (27.6 g in 100 mL water, 0.2 mol) and tetrabutyl-ammonium-hydroxide solution (40% in water, 1 .3 g, 5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours. Then the reaction mixture is diluted with 100 mL brine and stirred for 15 min, stop stirring, and remove the lower aqueous layer .
- n-butyllithium (56 mL, 2.5 M in hexane, 0.14 mol) is added to the mixture of Diisopropylamine (14.2 g, 0.15 mol) in 300 mL dry tetrahydrofuran at -10 °C, the resulting mixture is then stirred for 30 min at -10 °C.
- benzoyl chloride (15.5 g, 0.1 1 mol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 100 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer .
- Formaldehyde (37% in water, 24.3 g, 0.3 mol)
- K 2 C0 3 aqueous solution 27.6 g in 100 ml. water, 0.2 mol
- tetrabutyl-ammonium-hydroxide solution (40% in water, 1.3 g, 5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- benzoyl chloride (1.55 g, 1 1 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 15 ml. saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 2.43 g, 0.03 mol), K 2 C0 3 aqueous solution (2.76 g in 10 mL water, 0.02 mol) and tetrabutyl-ammonium-hydroxide solution (40% in water, 0.13 g, 0.5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- benzoyl chloride (1.55 g, 1 1 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 15 ml. saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 2.43 g, 0.03 mol), K 2 C0 3 aqueous solution (2.76 g in 10 mL water, 0.02 mol) and tetrabutyl-ammonium-hydroxide solution (40% in water, 0.13 g, 0.5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- acetyl chloride (0.47 g, 6 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 10 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 1 .2 g, 15 mmol)
- K 2 C0 3 aqueous solution (1.4 g in 5 mL water, 0.01 mol)
- tetrabutyl-ammonium-hydroxide solution (40% in water, 0.06 g, 0.25 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- 2,2-Dimethyl- propionyl chloride (0.72 g, 6 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 10 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 1 .2 g, 15 mmol), K 2 C0 3 aqueous solution (1 .4 g in 5 mL water, 0.01 mol) and tetrabutyl-ammonium-hydroxide solution (40% in water, 0.06 g, 0.25 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- Isobutyryl chloride (0.64 g, 6 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at - 10 °C, the reaction mixture is diluted with 10 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 1 .2 g, 15 mmol), K 2 C0 3 aqueous solution (1.4 g in 5 mL water, 0.01 mol) and tetrabutyl-ammonium-hydroxide solution (40% in water, 0.06 g, 0.25 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- n-butyllithium (56 mL, 2.5 M in hexane, 0.14 mol) is added to the mixture of HMDS (24.2 g, 0.15 mol) in 300 mL dry tetrahydrofuran at -10 °C, the resulting mixture is then stirred for 30 min at -10 °C.
- benzoyl chloride (15.5 g, 0.1 1 mol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 100 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer .
- Formaldehyde (37% in water, 24.3 g, 0.3 mol)
- K 2 C0 3 aqueous solution 27.6 g in 100 mL water, 0.2 mol
- tetrabutyl-ammonium-hydroxide solution (40% in water, 1.3 g, 5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- reaction mixture is diluted with 100 mL brine and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Lithium hydroxide monohydrate solution (15 g in 100 mL water, 0.36 mol) and tetrabutylammonium bromide (0.32 g, 1 mmol) are added to the remaining organic phase, stirred at r.t. for 2 hours.
- about 50 g of phosphoric acid 85% is added in order to set the pH to 3.0-4.0.
- 100 mL toluene and 100 mL brine is added. After phase separation and concentrated under vacuo.
- n-butyllithium (56 mL, 2.5 M in hexane, 0.14 mol) is added to the mixture of Diisopropylamine (14.2 g, 0.15 mol) in 300 mL dry tetrahydrofuran at -10 °C, the resulting mixture is then stirred for 30 min at -10 °C.
- benzoyl chloride (15.5 g, 0.1 1 mol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 100 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer .
- K 2 C0 3 aqueous solution 27.6 g in 100 mL water, 0.2 mol
- tetrabutyl-ammonium-hydroxide solution (40% in water, 1.3 g, 5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- reaction mixture is diluted with 100 mL brine and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Lithium hydroxide monohydrate solution (15 g in 100 mL water, 0.36 mol) and tetrabutylammonium bromide (0.32 g, 1 mmol) are added to the remaining organic phase, stirred at r.t. for 2 hours.
- about 50 g of phosphoric acid 85% is added in order to set the pH to 3.0-4.0. then 100 mL toluene and 100 mL brine is added. After phase separation and concentrated under vacuo.
- benzoyl chloride (1.55 g, 1 1 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 15 mL saturated aqueous ammonium chloride solution and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 2.43 g, 0.03 mol), K 2 C0 3 aqueous solution (2.76 g in 10 mL water, 0.02 mol) and tetrabutyl-ammonium-hydroxide solution (40% in water, 0.13 g, 0.5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours. Then the reaction mixture is diluted with 15 mL brine and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Lithium hydroxide monohydrate solution (1.5 g in 10 mL water, 0.036 mol) and tetrabutylammonium bromide (32 mg, 0.1 mmol) are added to the remaining organic phase, stirred at r.t. for 2 hours. Then , about 5 g of phosphoric acid 85% is added in order to set the pH to 3.0-4.0. then 15 mL toluene and 15 mL brine is added. After phase separation and concentrated under vacuo.
- benzoyl chloride (1.55 g, 1 1 mmol) is added to the reaction mixture at -10 °C, after about 1 hour at -10 °C, the reaction mixture is diluted with 15 mL saturated aqueous ammonium chloride solution and stirred for 15min, stop stirring, and remove the lower aqueous layer.
- Formaldehyde (37% in water, 2.43 g, 0.03 mol)
- K 2 C0 3 aqueous solution (2.76 g in 10 mL water, 0.02 mol)
- tetrabutyl-ammonium-hydroxide solution (40% in water, 0.13 g, 0.5 mmol) are added to the remaining organic phase, and heated to 50 °C , and stirred for 2 hours.
- reaction mixture is diluted with 15 mL brine and stirred for 15 min, stop stirring, and remove the lower aqueous layer.
- Lithium hydroxide monohydrate solution 1.5 g in 10 mL water, 0.036 mol
- tetrabutylammonium bromide 32 mg, 0.1 mmol
- about 5 g of phosphoric acid 85% is added in order to set the pH to 3.0-4.0.
- 15 mL toluene and 15 mL brine is added. After phase separation and concentrated under vacuo.
- reaction mixture is cooled to 25 °C, washed with 200 mL of water three times, then concentrated.
- the residue is dissolved in 400 mL of THF, MgCI 2 (18.0 g, 159 mm) and triethylamine (26.1 g, 258 mmol) are added.
- the reaction mixture is cooled to 5 °C, benzoyl chloride (36.4 g, 259 mmol) is added dropwise slowly, after addition, the mixture is stirred at 5 °C for 1 h, then warm to 10 °C and stirred for 15 h. 100 mL of water are added, followed by a solution of H 3 P0 4 (57.4 g, 510 mol) in water (100 mL).
- the organic phase is washed with saturated sodium chloride (200 mL) twice.
- Lithium hydroxide monohydrate solution 29.3 g in 200 mL of water, 698 mmol
- tetrabutyl ammonium bromide (0.65 g, 2 mmol)
- the mixture is stirred at 25 °C for 4 h.
- phosphoric acid 97% w/w
- pH is adjusted to 4-5 at 10 - 20 °C.
- the aqueous phase is removed and a saturated sodium chloride solution in water (200 mL) is added.
- the organic phase is separated and concentrated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2786929A CA2786929C (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
JP2012549244A JP5600183B2 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and methods for their preparation |
SI201130614T SI2526088T1 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
MX2012008483A MX2012008483A (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof. |
CN201180006875.7A CN102712585B (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
KR1020127021865A KR101463670B1 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
AU2011207020A AU2011207020B2 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
ES11734379.8T ES2550485T3 (en) | 2010-01-22 | 2011-01-21 | Neutral endopeptidase inhibitor intermediates and method of their preparation |
PL11734379T PL2526088T3 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
BR112012017869A BR112012017869A2 (en) | 2010-01-22 | 2011-01-21 | "neutral endopeptidase inhibitors intermediates and method of preparing them" |
EP11734379.8A EP2526088B1 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
US13/522,995 US9067883B2 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
RU2012135772/04A RU2564024C2 (en) | 2010-01-22 | 2011-01-21 | Intermediate products for producing neutral endopeptidase inhibitors and method for production thereof |
US14/739,172 US9278908B2 (en) | 2010-01-22 | 2015-06-15 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
HRP20151061TT HRP20151061T1 (en) | 2010-01-22 | 2015-10-06 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010070322 | 2010-01-22 | ||
CNPCT/CN2010/070322 | 2010-01-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/522,995 A-371-Of-International US9067883B2 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
US14/739,172 Continuation US9278908B2 (en) | 2010-01-22 | 2015-06-15 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011088797A1 true WO2011088797A1 (en) | 2011-07-28 |
Family
ID=44306404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/070458 WO2011088797A1 (en) | 2010-01-22 | 2011-01-21 | Intermediates of neutral endopeptidase inhibitors and preparation method thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US9067883B2 (en) |
EP (1) | EP2526088B1 (en) |
JP (1) | JP5600183B2 (en) |
KR (1) | KR101463670B1 (en) |
CN (2) | CN102712585B (en) |
AU (1) | AU2011207020B2 (en) |
BR (1) | BR112012017869A2 (en) |
CA (1) | CA2786929C (en) |
ES (1) | ES2550485T3 (en) |
HR (1) | HRP20151061T1 (en) |
MX (1) | MX2012008483A (en) |
PL (1) | PL2526088T3 (en) |
PT (1) | PT2526088E (en) |
RU (1) | RU2564024C2 (en) |
SI (1) | SI2526088T1 (en) |
WO (1) | WO2011088797A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8449890B2 (en) | 2011-02-17 | 2013-05-28 | Theravance, Inc. | Neprilysin inhibitors |
US8481044B2 (en) | 2011-02-17 | 2013-07-09 | Theravance, Inc. | Neprilysin inhibitors |
US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
US8563512B2 (en) | 2010-12-15 | 2013-10-22 | Theravance, Inc. | Neprilysin inhibitors |
US8586536B2 (en) | 2010-12-15 | 2013-11-19 | Theravance, Inc. | Neprilysin inhibitors |
US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
US8691868B2 (en) | 2011-11-02 | 2014-04-08 | Theravance, Inc. | Neprilysin inhibitors |
US8871792B2 (en) | 2012-06-08 | 2014-10-28 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
JP2015507015A (en) * | 2012-02-15 | 2015-03-05 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Method for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound |
US9045443B2 (en) | 2012-05-31 | 2015-06-02 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
US9108934B2 (en) | 2012-06-08 | 2015-08-18 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9126956B2 (en) | 2012-08-08 | 2015-09-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
WO2016074651A1 (en) | 2014-11-14 | 2016-05-19 | Zentiva, K.S. | A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377 |
WO2016128924A1 (en) | 2015-02-13 | 2016-08-18 | Novartis Ag | Process and intermediates for the preparation of nep inhibitors |
US9433598B2 (en) | 2015-02-11 | 2016-09-06 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid |
US9499487B2 (en) | 2011-05-31 | 2016-11-22 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9533962B2 (en) | 2015-02-19 | 2017-01-03 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
CN106380421A (en) * | 2016-08-26 | 2017-02-08 | 中国科学院上海有机化学研究所 | Synthetic method for Sacubitril |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
WO2017097275A1 (en) | 2015-12-11 | 2017-06-15 | Zentiva, K.S. | Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method |
WO2017098430A1 (en) | 2015-12-10 | 2017-06-15 | Novartis Ag | New process and intermediates |
WO2018007919A1 (en) | 2016-07-05 | 2018-01-11 | Novartis Ag | New process for early sacubitril intermediates |
WO2018033866A1 (en) | 2016-08-17 | 2018-02-22 | Novartis Ag | New processes and intermediates for nep inhibitor synthesis |
WO2018116203A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | New process for early sacubitril intermediates |
US10100021B2 (en) | 2016-03-08 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
WO2018196860A1 (en) * | 2017-04-28 | 2018-11-01 | 武汉朗来科技发展有限公司 | Ammonium carboxylate compound, crystal form and amorphous substance thereof, and preparation method therefor |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091364A1 (en) * | 2008-01-17 | 2009-10-13 | Novartis Ag | PROCESS FOR THE PREPARATION OF NEP INHIBITORS |
RU2564024C2 (en) * | 2010-01-22 | 2015-09-27 | Новартис Аг | Intermediate products for producing neutral endopeptidase inhibitors and method for production thereof |
KR101476937B1 (en) | 2010-08-23 | 2014-12-24 | 노파르티스 아게 | Process for the preparation of intermediates for the manufacture of nep inhibitors |
CA2902456A1 (en) | 2013-03-05 | 2014-09-12 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
MX2016009760A (en) | 2014-01-30 | 2016-11-08 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors. |
RU2016135057A (en) | 2014-01-30 | 2018-03-12 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | DERIVATIVES OF 5-BIPHENYL-4-HETEROARYL CARBONILAMINOPENTANIC ACID AS NEPRILISINE INHIBITORS |
CN106795099B (en) * | 2014-04-10 | 2019-11-26 | 南京奥昭生物科技有限公司 | For treating the prodrug and composition of hypertension and cardiovascular disease |
CN104860894B (en) * | 2015-06-10 | 2017-05-17 | 北京博全健医药科技有限公司 | Method for preparing cardiotonic drug LCZ696 |
CN112094198A (en) * | 2020-06-15 | 2020-12-18 | 南京红太阳医药研究院有限公司 | Synthesis method of N-nitroso-N-methyl-4-aminobutyric acid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
WO2008083967A2 (en) * | 2007-01-12 | 2008-07-17 | Novartis Ag | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
WO2009090251A2 (en) | 2008-01-17 | 2009-07-23 | Novartis Ag | New processes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69817974T2 (en) * | 1997-11-14 | 2004-07-22 | Schering Ag | A process for the preparation of pyrrolidinone derivatives |
JPH11152267A (en) * | 1997-11-20 | 1999-06-08 | Mitsui Chem Inc | Production of pyrrolidinone derivative |
EP1903027A1 (en) * | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
RU2564024C2 (en) * | 2010-01-22 | 2015-09-27 | Новартис Аг | Intermediate products for producing neutral endopeptidase inhibitors and method for production thereof |
-
2011
- 2011-01-21 RU RU2012135772/04A patent/RU2564024C2/en not_active IP Right Cessation
- 2011-01-21 CA CA2786929A patent/CA2786929C/en not_active Expired - Fee Related
- 2011-01-21 EP EP11734379.8A patent/EP2526088B1/en active Active
- 2011-01-21 CN CN201180006875.7A patent/CN102712585B/en active Active
- 2011-01-21 MX MX2012008483A patent/MX2012008483A/en active IP Right Grant
- 2011-01-21 SI SI201130614T patent/SI2526088T1/en unknown
- 2011-01-21 KR KR1020127021865A patent/KR101463670B1/en not_active IP Right Cessation
- 2011-01-21 JP JP2012549244A patent/JP5600183B2/en active Active
- 2011-01-21 BR BR112012017869A patent/BR112012017869A2/en not_active IP Right Cessation
- 2011-01-21 PT PT117343798T patent/PT2526088E/en unknown
- 2011-01-21 CN CN201410421991.0A patent/CN104262228B/en active Active
- 2011-01-21 PL PL11734379T patent/PL2526088T3/en unknown
- 2011-01-21 AU AU2011207020A patent/AU2011207020B2/en not_active Ceased
- 2011-01-21 US US13/522,995 patent/US9067883B2/en active Active
- 2011-01-21 ES ES11734379.8T patent/ES2550485T3/en active Active
- 2011-01-21 WO PCT/CN2011/070458 patent/WO2011088797A1/en active Application Filing
-
2015
- 2015-06-15 US US14/739,172 patent/US9278908B2/en active Active
- 2015-10-06 HR HRP20151061TT patent/HRP20151061T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
WO2008083967A2 (en) * | 2007-01-12 | 2008-07-17 | Novartis Ag | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
WO2009090251A2 (en) | 2008-01-17 | 2009-07-23 | Novartis Ag | New processes |
Non-Patent Citations (3)
Title |
---|
J. F. W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
P. G. M. WUTS; T. W. GREENE: "Greene's Protective Groups in Organic Synthesis", WILEY |
See also references of EP2526088A4 * |
Cited By (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9120747B2 (en) | 2010-12-15 | 2015-09-01 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10336773B2 (en) | 2010-12-15 | 2019-07-02 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9873696B2 (en) | 2010-12-15 | 2018-01-23 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8563512B2 (en) | 2010-12-15 | 2013-10-22 | Theravance, Inc. | Neprilysin inhibitors |
US8586536B2 (en) | 2010-12-15 | 2013-11-19 | Theravance, Inc. | Neprilysin inhibitors |
US10759813B2 (en) | 2010-12-15 | 2020-09-01 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9845332B2 (en) | 2010-12-15 | 2017-12-19 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9688692B2 (en) | 2010-12-15 | 2017-06-27 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11261197B2 (en) | 2010-12-15 | 2022-03-01 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9555041B2 (en) | 2010-12-15 | 2017-01-31 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11851443B2 (en) | 2010-12-15 | 2023-12-26 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9388145B2 (en) | 2010-12-15 | 2016-07-12 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9120758B2 (en) | 2010-12-15 | 2015-09-01 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9725448B2 (en) | 2011-02-17 | 2017-08-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9487514B2 (en) | 2011-02-17 | 2016-11-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8481044B2 (en) | 2011-02-17 | 2013-07-09 | Theravance, Inc. | Neprilysin inhibitors |
US10130642B2 (en) | 2011-02-17 | 2018-11-20 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9724359B2 (en) | 2011-02-17 | 2017-08-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9334245B2 (en) | 2011-02-17 | 2016-05-10 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8449890B2 (en) | 2011-02-17 | 2013-05-28 | Theravance, Inc. | Neprilysin inhibitors |
US8846913B2 (en) | 2011-02-17 | 2014-09-30 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8853427B2 (en) | 2011-02-17 | 2014-10-07 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
US8993752B2 (en) | 2011-05-31 | 2015-03-31 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9422245B2 (en) | 2011-05-31 | 2016-08-23 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9499487B2 (en) | 2011-05-31 | 2016-11-22 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
US9828367B2 (en) | 2011-05-31 | 2017-11-28 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9771337B2 (en) | 2011-05-31 | 2017-09-26 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11547687B2 (en) | 2011-11-02 | 2023-01-10 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8691868B2 (en) | 2011-11-02 | 2014-04-08 | Theravance, Inc. | Neprilysin inhibitors |
US12016835B2 (en) | 2011-11-02 | 2024-06-25 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10744104B2 (en) | 2011-11-02 | 2020-08-18 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10123984B2 (en) | 2011-11-02 | 2018-11-13 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9150500B2 (en) | 2011-11-02 | 2015-10-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9682052B2 (en) | 2011-11-02 | 2017-06-20 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
JP2015507015A (en) * | 2012-02-15 | 2015-03-05 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Method for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound |
US9045443B2 (en) | 2012-05-31 | 2015-06-02 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
US9683002B2 (en) | 2012-06-08 | 2017-06-20 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9884807B2 (en) | 2012-06-08 | 2018-02-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9981999B2 (en) | 2012-06-08 | 2018-05-29 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11174219B2 (en) | 2012-06-08 | 2021-11-16 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US8871792B2 (en) | 2012-06-08 | 2014-10-28 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9670140B2 (en) | 2012-06-08 | 2017-06-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10829438B2 (en) | 2012-06-08 | 2020-11-10 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9108934B2 (en) | 2012-06-08 | 2015-08-18 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10315984B2 (en) | 2012-06-08 | 2019-06-11 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9126956B2 (en) | 2012-08-08 | 2015-09-08 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9873685B2 (en) | 2012-08-08 | 2018-01-23 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10570120B2 (en) | 2012-08-08 | 2020-02-25 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11919888B2 (en) | 2012-08-08 | 2024-03-05 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11124502B2 (en) | 2012-08-08 | 2021-09-21 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US9670186B2 (en) | 2012-08-08 | 2017-06-06 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US10189823B2 (en) | 2012-08-08 | 2019-01-29 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
US11634413B2 (en) | 2012-08-08 | 2023-04-25 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
WO2016074651A1 (en) | 2014-11-14 | 2016-05-19 | Zentiva, K.S. | A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377 |
US9433598B2 (en) | 2015-02-11 | 2016-09-06 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid |
US9670143B2 (en) | 2015-02-11 | 2017-06-06 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid |
US9868698B2 (en) | 2015-02-11 | 2018-01-16 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid |
WO2016128924A1 (en) | 2015-02-13 | 2016-08-18 | Novartis Ag | Process and intermediates for the preparation of nep inhibitors |
US11033533B2 (en) | 2015-02-19 | 2021-06-15 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
US9533962B2 (en) | 2015-02-19 | 2017-01-03 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
US11642332B2 (en) | 2015-02-19 | 2023-05-09 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
US10548879B2 (en) | 2015-02-19 | 2020-02-04 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
US9872855B2 (en) | 2015-02-19 | 2018-01-23 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
US10172834B2 (en) | 2015-02-19 | 2019-01-08 | Theravance Biopharma R&D Ip, Llc | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
WO2017098430A1 (en) | 2015-12-10 | 2017-06-15 | Novartis Ag | New process and intermediates |
US11434192B2 (en) | 2015-12-10 | 2022-09-06 | Novartis Ag | Process and intermediates |
WO2017097275A1 (en) | 2015-12-11 | 2017-06-15 | Zentiva, K.S. | Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method |
US11718591B2 (en) | 2016-03-08 | 2023-08-08 | Theravance Biopharma R&D Ip, Llc | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof |
US11230536B2 (en) | 2016-03-08 | 2022-01-25 | Theravance Biopharma R&D Ip, Llc | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
US10752599B2 (en) | 2016-03-08 | 2020-08-25 | Theravance Biopharma R&D Ip, Llc | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
US10472335B2 (en) | 2016-03-08 | 2019-11-12 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
US10100021B2 (en) | 2016-03-08 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
WO2018007919A1 (en) | 2016-07-05 | 2018-01-11 | Novartis Ag | New process for early sacubitril intermediates |
WO2018033866A1 (en) | 2016-08-17 | 2018-02-22 | Novartis Ag | New processes and intermediates for nep inhibitor synthesis |
CN106380421A (en) * | 2016-08-26 | 2017-02-08 | 中国科学院上海有机化学研究所 | Synthetic method for Sacubitril |
WO2018116203A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | New process for early sacubitril intermediates |
US11161803B2 (en) | 2017-04-28 | 2021-11-02 | Wuhan Ll Science And Technology Development Co., Ltd. | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof |
WO2018196860A1 (en) * | 2017-04-28 | 2018-11-01 | 武汉朗来科技发展有限公司 | Ammonium carboxylate compound, crystal form and amorphous substance thereof, and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
US20150274642A1 (en) | 2015-10-01 |
MX2012008483A (en) | 2012-08-15 |
JP2013517306A (en) | 2013-05-16 |
BR112012017869A2 (en) | 2019-09-24 |
SI2526088T1 (en) | 2015-12-31 |
RU2012135772A (en) | 2014-02-27 |
CN104262228A (en) | 2015-01-07 |
CA2786929C (en) | 2017-10-24 |
EP2526088B1 (en) | 2015-08-05 |
KR20120120947A (en) | 2012-11-02 |
CA2786929A1 (en) | 2011-07-28 |
EP2526088A4 (en) | 2013-08-21 |
JP5600183B2 (en) | 2014-10-01 |
PT2526088E (en) | 2015-11-03 |
US9278908B2 (en) | 2016-03-08 |
ES2550485T3 (en) | 2015-11-10 |
US20120289710A1 (en) | 2012-11-15 |
PL2526088T3 (en) | 2016-01-29 |
HRP20151061T1 (en) | 2015-12-04 |
US9067883B2 (en) | 2015-06-30 |
EP2526088A1 (en) | 2012-11-28 |
KR101463670B1 (en) | 2014-11-19 |
CN104262228B (en) | 2017-01-18 |
AU2011207020A1 (en) | 2012-08-09 |
AU2011207020B2 (en) | 2014-04-17 |
CN102712585B (en) | 2015-06-24 |
CN102712585A (en) | 2012-10-03 |
RU2564024C2 (en) | 2015-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9278908B2 (en) | Intermediates of neutral endopeptidase inhibitors and preparation method thereof | |
AU2008204546B2 (en) | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | |
EP2890672B1 (en) | Processes for preparing intermediates for the manufacture of nep inhibitors | |
EP2609075B1 (en) | Process for the preparation of intermediates for the manufacture of nep inhibitors | |
US20190256454A1 (en) | New process for early sacubitril intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180006875.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11734379 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6167/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2786929 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011207020 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011734379 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13522995 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012549244 Country of ref document: JP Ref document number: MX/A/2012/008483 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011207020 Country of ref document: AU Date of ref document: 20110121 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127021865 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012135772 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012017869 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012017869 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120718 |